Viking Therapeutics: Oppenheimer sees a price target of $120 - Analysts assign a 90% success chance to the pipeline

Viking Therapeutics (VKTX) focuses on the rapidly growing market for obesity therapies with its dual GLP-1/GIP agonist. Oppenheimer raises the price target to $120 and increases the probability of success for the drug VK2735 to 90%. Recent clinical data shows the maintenance of up to 97% of weight loss with reduced dosing intervals. Focus on the growing obesity market Viking Therapeutics (VKTX) is a biopharmaceutical company in the clinical development phase specializing in therapies for metabolic and endocrine disorders. Its business model...